MedPath
Found 1 clinical trials|View Analysis
Sort by:

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1
Not yet recruiting
Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
Biological: Synthetic long peptide personalized cancer vaccine
Drug: Poly ICLC
Biological: Nivolumab
Device: Signatera assay
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
16
Registration Number
NCT06529822
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath